Yale University

EliScholar – A Digital Platform for Scholarly Publishing at Yale
Public Health Theses

School of Public Health

January 2015

The Epidemiology Of Clostridium Difficile
Infections Among Oncology Patients
Yunyoung Gina Chang
Yale University, ginayc@gmail.com

Follow this and additional works at: http://elischolar.library.yale.edu/ysphtdl
Recommended Citation
Chang, Yunyoung Gina, "The Epidemiology Of Clostridium Difficile Infections Among Oncology Patients" (2015). Public Health
Theses. 1038.
http://elischolar.library.yale.edu/ysphtdl/1038

This Open Access Thesis is brought to you for free and open access by the School of Public Health at EliScholar – A Digital Platform for Scholarly
Publishing at Yale. It has been accepted for inclusion in Public Health Theses by an authorized administrator of EliScholar – A Digital Platform for
Scholarly Publishing at Yale. For more information, please contact elischolar@yale.edu.

The Epidemiology of Clostridium difficile
Infections among Oncology Patients

M.P.H. Thesis
Department of Epidemiology of Microbial Diseases
Yale School of Public Health

Yunyoung Gina Chang
April 2015

First Reader: Dr. Louise-Marie Dembry
Second Reader: Dr. David Banach

Acknowledgements

I would like to thank Dr. Louise-Marie Dembry and Dr. David Banach for their patience, support
and mentorship throughout the past year. I am immensely grateful for their generous donation of
their time and for their constant willingness to make availabilities in their busy schedules for me.
Without their steadfast encouragement and guidance, this thesis would not have been possible. I
would also like to thank Peter Longley from the Yale-New Haven Hospital’s Data Analytics Team
and Linda Sullivan for their help in obtaining data for the study. Finally, I would like to thank my
adviser Dr. Sunil Parikh for advising me throughout the MPH program and for his help in
connecting me to this research opportunity.

2

Table of Contents
Abstract ........................................................................................................................ 4
Introduction ................................................................................................................. 5
Methods ........................................................................................................................ 9
Results ........................................................................................................................ 13
Table 1: Demographic Factors, Medical History, and Clinical Factors by Group .............................. 15
Table 2: Antibiotics Received by Group ................................................................................................... 16
Table 3: Univariate Logistic Regression of Potential Risk Factors in Cases Compared to Control
Groups ......................................................................................................................................................... 18
Table 4: Univariate Logistic Regression of Antibiotic Use in Cases Compared to Control Groups .. 20
Table 5: Multivariate Logistic Regression Compared to Negative Test Control Group ..................... 21
Table 6: Multivariate Logistic Regression Compared to Matched Control Group ............................. 23

Discussion................................................................................................................... 23
References .................................................................................................................. 34
Appendix .................................................................................................................... 39

3

Abstract
	
  

Clostridium difficile is the leading cause of hospital-acquired diarrhea. Oncology patients are a
group of immunosuppressed patients who are at increased risk for C. difficile infection. The primary
objective of this study was to describe the demographic factors, medical history, and clinical
characteristics and identify risk factors for C. difficile infection among oncology patients. A
retrospective chart review was conducted for this case-control study. Seventy-seven cases were
compared to two control groups; one control group of patients with diarrhea but whose stool samples
were tested and were negative for C. difficile (n=77), and a second control group of patients matched to
cases based on hospital ward and date of discharge (n=152). Multivariate analyses were performed using
logistic regression. Adjusting for all other variables, days of hospitalization prior to test (OR=1.075, 95%
CI 1.027, 1.124), fever on test date (OR=5.232, 95% CI 1.460, 18.755), history of C. difficile
(OR=32.433, 95% CI 3.513, 299.445), and hypotension on test date (OR=9.245, 95% CI 1.232, 69.183)
were significantly associated with C. difficile infection in cases compared to the negative test control
group. When cases were compared to the matched control group, age (OR=1.042, 95% CI 1.006, 1.079),
history of any co-infection (OR=5.614, 95% CI 1.878, 16.787), blood transfusion (OR=3.200, 95% CI
1.251, 8.183), prior receipt of cephalosporins (OR=4.214, 95% CI 1.371, 12.952) or metronidazole
(OR=16.005, 95% CI 3.958, 64.713), chemotherapy (OR=5.069, 95% CI 1.609, 15.972), history of C.
difficile (OR=27.806, 95% CI 2.484, 311.290), and use of a nasogastric tube (OR=6.988, 95% CI 1.339,
36.477) were significantly associated with C. difficile infection. Risk factors for C. difficile infection
differed when comparing cases to the negative test control group and to the matched control group;
however, prior history of C. difficile was a common risk factor. Based on the analysis of the matched
control group, reduction in cephalosporin and metronidazole use, particularly among patients with a
history of C. difficile infection, recent chemotherapy or blood transfusions, or presence of a nasogastric
tube, may reduce the risk of C. difficile infection and should be a focus of future study and intervention.
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Introduction
	
  

Clostridium difficile is a gram-positive, anaerobic bacterium that is the leading cause of
hospital-acquired diarrhea [1]. C. difficile has a wide variety of clinical presentations, ranging from
asymptomatic carriage to mild self-limited diarrhea, pseudomembranous colitis, toxic megacolon
perforation, and sepsis [2]. Since 2002, there has been a consistent rise in the rates of C. difficile in
Canada, the United States, and Europe. In 2011, over 450,000 incident cases of C. difficile and
29,000 deaths were estimated to have occurred in the United States [3]. This is a significant increase
in the number of C. difficile cases in just five years. In 2006, United States hospitals reported a C.
difficile diagnosis discharge rate of 300,000 cases per year, a doubling of cases since 2000 [4]. Thus,
C. difficile cases have been steadily increasing over the recent decades, which represent significant
patient mortality and morbidity nationwide. This increase in the number of C. difficile cases has
been attributed to a newly identified strain, C. difficile BI/NAP1/027, which may be more virulent
than previous strains [4]. There have been other changes in the epidemiology of C. difficile in recent
years that exacerbate its economic and health consequences. Currently, C. difficile-associated
disease is estimated to incur costs of up to $4.8 billion per year [2, 3].
C. difficile has the ability to form spores, which contributes to transmission due to
environmental contamination, particularly in healthcare settings. The spores are able to persist on
environmental surfaces for up to several months [5]. The spores are heat and alcohol resistant, and
contamination of surfaces often remains after cleaning and disinfection with standard disinfectants
[6, 7]. Environmental transmission contributes to the exogenous acquisition of C. difficile which
occurs through the fecal-oral transmission of spores. In hospital or healthcare settings, transmission
through contact with contaminated residual spores present on healthcare professionals’ hands and
clothing is common [5]. Acquisition of C. difficile can also be endogenous as well. Antibiotic use
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results in the disruption of normal colonic flora which facilitates the proliferation of C. difficile and
subsequent illness when toxigenic strains proliferate [6].
More than 90% of C. difficile infections have been shown to occur either during or after
antibiotic treatment, likely as a result of the disruption of the normal microbiota [5]. However, host
factors also play a role in the development of illness. Even if a toxigenic strain is acquired, illness
may not result if the host is able to mount an IgG antibody response, which would result in
asymptomatic colonization. Asymptomatic colonization with C. difficile also occurs if a nontoxigenic strain is acquired [4]. It has been estimated that 3% of the general, healthy population is
asymptomatically colonized with C. difficile, but carriage rates are higher in patients who have been
previously hospitalized or have received antibiotics [5].
Pathogenicity of C. difficile is attributable to two main endotoxins, toxin A and toxin B.
Non-toxigenic strains of C. difficile are generally not pathogenic [8]. In most cases, both toxins A
and B are produced during C. difficile infection [9]. Once C. difficile proliferates and is endocytosed
in the colon, toxins A and B induce fluid secretion, inflammation, and mucosal damage [5]. Cell
death results from the production of tumor necrosis factor-alpha and pro-inflammatory interleukins.
The combined tissue damage results in diarrhea or pseudomembranous colitis [5, 8]. Typical
treatment for first occurrence of mild to moderate C. difficile is metronidazole. Oral vancomycin is
recommended for more severe infections and for second or later recurrent episodes. Severely ill
patients are typically identified as such if they present with leukocytosis, elevated creatinine levels,
elevated lactate levels, hypotension, shock, ileus, colonic perforation, or megacolon, and a
colectomy may be necessary for these patients [6]. Recently, fecal microbiota transplant has also
been suggested as a possible treatment for C. difficile, particularly for patients with recurrent C.
difficile infection and antimicrobial treatment failure. Fecal microbiota transplantation involves the
infusion of healthy donor feces in the patient in order to restore the intestinal microbiota, and thus,
6

prevent C. difficile colonization. Fecal microbiota transplantation has been shown to have a very
high efficacy, with no further recurrence of C. difficile seen in 92% of treated cases [10, 11].
However, further research into fecal microbiota transplantation is needed as there have been limited
controlled studies to elucidate the benefits and potential adverse effects of this treatment.
There are many risk factors for C. difficile infection. A systematic review found consistent
evidence that increasing age, severity of underlying diseases, non-surgical gastrointestinal
procedures, nasogastric tubes, anti-ulcer medications, increasing duration of hospital stay,
increasing duration of antibiotic course, and the use of multiple antibiotics are associated with
increased risk of C. difficile infection [12]. However, older age and severity of underlying illnesses
may have a confounding association with risk of C. difficile infection, as older patients and patients
with more severe illnesses are more likely to have an increased length of hospital stay and
subsequently, increased potential exposure to C. difficile [13]. Among antibiotics, broad-spectrum
antibiotics – in particular, cephalosporins, clindamycin, and fluoroquinoloes – as well as penicillin
have been the most frequently associated with increased risk of C. difficile infection. A proposed
mechanism has been that these particular antibiotics or antibiotics classes have a large disruptive
impact on the normal intestinal flora, and thus, facilitate colonization of toxigenic C. difficile strains
[5, 13]. Gastrointestinal stimulants, stool softeners, and enemas have also been associated with
increased risk of C. difficile-associated diarrhea for the similar proposed mechanism of the
disruption of the normal intestinal flora [13].
Immunosuppression is another risk factor for C. difficile infection and has been associated
with severe C. difficile-associated illness. One study showed that patients who had been
immunosuppressed due to medications such as corticosteroids and chemotherapeutic drugs or due to
underlying conditions such as hematologic malignancies, HIV, and other autoimmune disorders
were at higher risk of developing severe C. difficile infection resulting in fulminant colitis,
7

colectomy, or death [14]. Of the immunosuppressed patients, patients who had received lung
transplants were particularly susceptible to developing fulminant C. difficile colitis [14]. Kidneypancreas transplant recipients have also been shown to have a high incidence of C. difficile colitis
[15]. Another single hospital-based study also found higher rates of infections in the nephrology,
hematology, and organ transplantation wards compared to other wards, corroborating studies that
suggest transplant recipients may be more susceptible to C. difficile infections due to their
immunosuppressed state [16].
Cancer patients are another group of immunosuppressed individuals susceptible to C.
difficile infection. A case report implicated chemotherapeutic agents as a risk factor for C. difficile
infection, independent of previous antibiotic exposure [17]. A review of published cases of C.
difficile infection in patients who have received chemotherapeutic agents reported on various
classes of chemotherapeutic agents associated with C. difficile colitis. Methotrexate was the most
commonly received chemotherapeutic drug among patients who developed C. difficile, followed by
doxorubicin and cyclophosphamide, and then fluorouracil. There were no significant associations
among C. difficile infection and type of cancer [18]. Although the pathogenesis of chemotherapeutic
agents in facilitating C. difficile infections is yet unclear, chemotherapeutic agents have been known
to cause extensive inflammatory damages in the bowel and alter the normal gut flora. Many
chemotherapeutic agents cause desquamation and necrosis, which may result in an adequate
anaerobic environment for the proliferation of C. difficile [18]. In an outpatient case-control study
that examined risk factors for C. difficile infections among cancer patients, no significant
association between any chemotherapy or treatment and the development of C. difficile was found.
The only significant associations found in this study were exposure to clindamycin and thirdgeneration cephalosporins and recent prolonged hospitalization [19]. Another case-control study
examined risk factors for C. difficile during an outbreak in an oncology unit. Compared to patients
8

in the unit with diarrhea but negative for C. difficile, patients with C. difficile infection were more
likely to have received chemotherapy. Receipt of both chemotherapy and exposure to antibiotics
increased the risk of C. difficile infection [20].
Although studies have shown that C. difficile has been associated with significant mortality
and morbidity and that there are many risk factors for C. difficile infection, there have been limited
studies examining C. difficile in cancer patients. Incidences of C. difficile in cancer patients have
previously been published as case reports, but there have been few comprehensive studies
examining risk factors among cancer patients. Additionally, current research has been limited in
showing consistent associations between specific chemotherapeutic drugs, other types of cancer
treatments, types of cancers, and specific antibiotics with C. difficile infections in cancer patients.
This study will address this gap in the current literature and aim to identify risk factors associated
with C. difficile infections in cancer patients by assessing various demographic and clinical
variables as well as previous medical history including prior antibiotic use and types of cancer
treatment received.

Methods
	
  

Study design and subjects
The study utilized a retrospective medical records review. Medical records of patients over
the age of 18 years admitted to the oncology wards at Yale-New Haven Hospital between February
1, 2013 and June 4, 2014 were eligible for enrollment in the study. The exclusion criterion was
patients aged 18 years or younger without an oncology diagnosis.
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The study design was case-control with two separate control arms. Cases were defined as
inpatient oncology patients whose stools tested positive for C. difficile through the Yale-New Haven
Hospital Microbiology Laboratory. The Yale-New Haven Hospital Microbiology Laboratory
performs a rapid glutamate dehydrogenase (GDH) antigen enzyme immunoassay (EIA) test on all
stool samples, and if positive, performs a reflex cell culture cytotoxin test. If both tests are negative,
then the patient is determined to be negative for C. difficile. If both tests are positive, then the
patient is determined to be positive for C. difficile infection. However, if the GDH antigen EIA test
is positive but the toxin EIA test is negative, a cytotoxin neutralization test in cell culture is
performed on the sample. If this is positive, then the patient is determined to have C. difficile
disease, while if it is negative, then the patient is determined to be colonized with C. difficile and is
not indicative of disease or active infection.
There were two control groups in this study. The first control group consisted of patients
presenting with loose stools during the admission period and whose stools were submitted to the
Microbiology Laboratory but tested negative for C. difficile. This control group was selected in
order to determine risk factors for C. difficile infection compared to oncology patients who
presented with loose stools but did not have C. difficile. The negative C. difficile test control
subjects were selected at random using the random number generator function on Microsoft Excel
from a computer-generated list of all patients who had been tested for C. difficile during the study
period and whose stools had been submitted from the oncology wards.
A second control group consisted of oncology patients matched to cases based on hospital
ward and dates of admission in order to control for environmental exposure to C. difficile [21]. This
control group was matched to cases on a 1:2 case-control ratio. From a computer-generated list of
all patients discharged from the oncology wards during the study period, patients were matched to
cases manually, first by hospital ward, and then by discharge date. Control patients were matched to
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cases using a discharge date range of ±3 days. If a case had more than two control patients matched
by hospital ward and discharge date, two control patients were selected at random using the random
number generator function on Microsoft Excel.

Data Collection
All subjects, cases and controls, were assigned a subject identification number, which was
used for data entry in order to eliminate patient identifiable information on data forms. All patient
medical records were accessed through the electronic medical record system. Data was stored both
on paper and electronically. Paper forms were kept in a locked storage cabinet. Electronic data was
entered on a Microsoft Excel spreadsheet and stored on a HIPAA-secured network accessed through
an encrypted computer.
Multiple demographic and clinical variables were abstracted from patient medical records.
The relevant risk period for C. difficile infection was established as 90 days prior to C. difficile test
for the cases and the negative test control group, and 90 days prior to admission date for the
matched control group. Demographic data such as age of subject and sex were collected. Dates of
index admission and discharge and cumulative days of hospitalization in the 90 days prior to the C.
difficile test (for the cases and negative test control group) or the index admission (for the matched
control group) were recorded. Previous medical history such as prior history of C. difficile, type of
cancer, stage of cancer, and cancer treatment (chemotherapy, surgery, stem cell therapy, blood
transfusion, radiation therapy) received in the 90 days prior to the test or the index discharge were
also recorded. Clinical variables included vancomycin-resistant enterococcus (VRE) colonization
status, co-infections, indwelling medical devices on current admission, clinical presentation, and
clinical outcome and treatment. For clinical presentation, the variables of elevated creatinine, fever,
hypotension, and tachycardia were assessed at the time of the C. difficile test, while elevated lactic
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acid, loose bowel movements, and neutropenia were assessed in the 90 days prior to the test.
Elevated creatinine was defined as equal to or greater than 1.5 times the creatinine level on index
admission, elevated lactic acid was defined as greater than 1.2 mmol/L, fever was defined as equal
to or greater than a temperature of 100.4°F, hypotension was defined as systolic blood pressure
equal to or less than 90 mmHg, and tachycardia was defined as heart rate equal to or greater than
110 beats per minute. Antibiotics received in the risk period were noted, as well as whether they
were received at the time of the test, prior to index admission, or discontinued after diagnosis.
Univariate analysis was conducted for all variables to determine the descriptive statistics
such as mean, frequencies, and standard deviations for each patient group. For the categorical
variables, logistic regression and the Fisher’s exact test was used to determine whether variables
were significantly associated with C. difficile infection. For continuous variables, the Student’s t test
was used to determine association. Conditional logistic regression was used to find associations
between the cases and the matched control group. For the multivariate model, all variables were
input into the model and a backward stepwise elimination strategy was used to obtain the final
model. All tests were two-tailed with a significance level of α=0.05. Data were processed and
analyzed using Microsoft Excel (version 14.32, Microsoft Corporation) and SAS (version 9.3, SAS
Institute, Inc.) software.

Study Approval
The study design and all protocols were reviewed and approved by the Institutional Review
Board at Yale University.
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Results
	
  

Eighty-one cases had a positive C. difficile test from the oncology wards during the period
February 1, 2013 to June 4, 2014. Four cases were excluded because the patients did not have
cancer, and a total of 77 cases met the eligibility criteria and were included in the study as cases. Six
hundred seventy patients had a negative C. difficile test while on one of the oncology wards during
the study period. Of this group of patients, 77 controls were selected for the negative test control
group through randomization. A total of 6,933 patients were discharged during the study period
from the oncology wards. Of this patient population, patients were matched to cases based on ward
and discharge date as described in the methods. Two control subjects were matched to each case
with the exclusion of two cases. For these two cases, only one control for each case was found to
meet the matching criteria. The study included 306 subjects in total, with 77 cases, 77 patients in the
negative test control group, and 152 patients in the matched control group.
Table 1 summarizes the demographic and clinical characteristics of subjects in all three
groups. Clinical presentation on the C. difficile test date was recorded for cases and the negative test
control group but not the matched control group since the matched control group was not tested for
C. difficile. Significant differences between cases and the negative test control group were found in
the proportion of subjects with prior history of C. difficile (p=0.0026), mean days of hospitalization
in the 90 days prior to the test (p=0.0028), history of stem cell therapy (p=0.0046), and fever on the
test date (p=0.0032). Significant differences between cases and the matched control group were
found in mean age (p=0.0011), proportion of subjects with prior history of C. difficile (p<0.0001),
history of blood transfusion (p=0.0134), any co-infection (p<0.0001), bloodstream infection
(p=0.0438), wound/skin infection (p=0.0033), urinary tract infection (p=0.0171), and pneumonia
(p=0.0059). The difference in proportion of subjects in each group who received chemotherapy in
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the 90 days prior to the test date or index discharge was not significant between cases and the two
groups. However, the most common chemotherapeutic agents received in each group varied. For
cases, the most common chemotherapeutic drugs received were cytarabine (7.14%), doxorubicin
(5.56%), cyclophosphamide (5.56%), irinotecan (5.56%), and paclitaxel (5.56%). In the negative
test control group, the most common chemotherapeutic drugs received were cytarabine (7.69%),
idarubicin (6.92%), cyclophosphamide (6.15%), and melphalan (6.15%), while in the matched
control group, they were cytarabine (7.28%), cisplatin (7.28%), cyclophosphamide (6.80%),
etoposide (6.63%), and methotrexate (5.53%).
Table 2 displays various antibiotics received in all three groups. A significantly greater
number of cases received clindamycin (p=0.0314) and metronidazole (p=0.0329) in the 90 days
prior to their C. difficile test compared to the negative test control group. There was also a
significantly higher proportion of individuals who received beta-lactams/beta-lactamase inhibitor
(BLI) (p=0.0018), clindamycin (p=0.0065), and fluoroquinolones (p=0.0069) prior to admission in
the cases compared to the negative test control group. Beta-lactams/BLI (p=0.0205) and
cephalosporins (p=0.0230) were discontinued after diagnosis in significantly higher numbers in the
cases compared to the negative test control group. There were no significant differences in
antibiotics received at the time of the test between the cases and the negative test control group. For
antibiotics received in the 90 days prior to the test or index discharge in cases compared to the
matched control group, proportions of patients who received beta-lactams (p=0.0182), betalactams/BLI (p=0.0002), cephalosporins (p=0.0364), metronidazole (p<0.0001), and intravenous
vancomycin (0.0002) were significantly higher in cases. Additionally, a significantly higher number
of cases received beta-lactams (p=0.0187), beta-lactams/BLI (p<0.0001), cephalosporins
(p=0.0028), clindamycin (p=0.0079), fluoroquinolones (p<0.0001), metronidazole (p<0.0001),
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sulfonamides (p=0.0438), and intravenous vancomycin (<0.0001) prior to admission compared to
the matched control group.

Table 1: Demographic Factors, Medical History, and Clinical Factors by Group
Characteristics

Mean age (years)
Male
Mean days of hospitalization
Prior history of C. difficile
VRE colonization
Cancer type
Solid tumors
Hematologic cancers
Cancer treatment
Blood transfusion
Chemotherapy
History of stem cell
therapy
Radiation therapy
Surgery
Indwelling medical devices
Central venous catheter
Enteral feeding
Mechanical ventilation
Nasogastric tube
TPN
Co-infections
Any co-infection
Blood stream-infection
Pneumonia
Urinary tract infection
Would/skin infection
Clinical presentation
Elevated creatinine
Elevated lactic acid
Fever
Hypotension
Loose bowel movements
Neutropenia
Tachycardia

Negative Test Control
(n=77)

Case (n=77)
%
63.37 ± 13.24
40.26
15.97 ± 18.81
18.18
20.69

No.

No.

14
12

%
61.41 ± 13.85
40.26
8.88 ± 8.13
2.6
12.96

72.73
32.47

56
25

38.96
67.53

Matched Control
(n=152)
No.

2
7

%
56.68 ± 14.80
38.16
13.37 ± 14.11
0.66
14.29

61.04
44.16

47
34

72.37
27.63

110
42

30
52

37.66
72.73

29
56

23.03
60.53

35
92

3.90

3

19.48

7.79
36.36

6
28

63.64
3.90
3.90
15.58
6.49

31

31

7.24

58
1
13

9.09
23.38

15
7
18

10.53
36.18

11
16
55

49
3
3
12
5

68.83
6.49
6.49
12.99
3.9

53
5
5
10
3

52.63
5.92
4.61
7.24
3.95

80
9
7
11
6

51.95
11.69
12.99
14.29
11.69

40
9
10
11
9

48.05
5.19
9.09
15.58
10.39

37
4
7
12
8

19.74
3.95
2.63
1.97
4.61

30
6
4
3
7

1.30
12.99
24.68
11.69
41.56
33.77
28.57

1
10
19
9
32
26
22

2.6
3.9
6.49
2.60
29.87
31.17
22.08

2
3
5
2
23
24
17
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Table 2: Antibiotics Received by Group

%

No.

Negative Test
Control (n=77)
%
No.

11.69
58.44
5.19
59.74
12.99
0.00
1.30
53.25
2.60
37.66
14.29
0.00
49.35
2.60

9
45
4
46
10
0
1
41
2
29
11
0
38
2

9.09
45.45
1.30
49.35
2.60
0.00
0.00
50.65
0.00
20.78
12.99
0.00
41.56
0.00

7
35
1
38
2
0
0
39
0
16
10
0
32
0

3.29
32.24
1.32
44.74
5.92
0.66
1.32
44.08
0.00
9.21
9.87
0.66
24.34
0.00

5
49
2
68
9
1
2
67
0
14
15
1
37
0

7.79
33.77
1.30
28.57
10.39
1.30
46.75
2.60
10.39
11.69
24.68
1.30

6
26
1
22
8
1
36
2
8
9
19
1

2.60
11.69
0.00
16.88
0.00
0.00
24.68
0.00
12.99
9.09
11.69
0.00

2
9
0
13
0
0
19
0
10
7
9
0

1.32
7.89
0.00
11.84
1.97
1.32
14.47
0.00
1.97
3.95
5.26
0.00

2
12
0
17
3
2
22
0
3
6
8
0

5.19
24.68
1.30
6.49
7.79
10.39
5.19
23.38

4
19
1
5
6
8
4
18

3.90
28.57
0.00
11.69
19.48
12.99
5.19
15.58

3
22
0
9
15
10
4
12

25.00
38.10
80.00
14.29
0.00
35.29

1
8
4
1
0
6

33.33
4.76
11.11
0.00
40.00
0.00

1
1
1
0
4
0

Antibiotic
Antibiotic received in 90 days prior to test
Beta-lactams
Beta-lactams/BLI
Carbapenems
Cephalosporins
Clindamycin
Colistin
Daptomycin
Fluoroquinolones
Fosfomycin
Metronidazole
Sulfonamides
Tigecycline
Vancomycin (intravenous)
Vancomycin (oral)
Antibiotic received prior to admission a
Beta-lactams
Beta-lactams/BLI
Carbapenems
Cephalosporins
Clindamycin
Daptomycin
Fluoroquinolones
Fosfomycin
Metronidazole
Sulfonamides
Vancomycin (intravenous)
Vancomycin (oral)
Antibiotic received at time of test a
Beta-lactams
Beta-lactams/BLI
Carbapenems
Cephalosporins
Fluoroquinolones
Metronidazole
Sulfonamides
Vancomycin (intravenous)
Antibiotic discontinued after diagnosis a
Beta-lactams
Beta-lactams/BLI
Cephalosporins
Clindamycin
Metronidazole
Vancomycin (intravenous)
a

Case (n=77)

Matched Control
(n=152)
%
No.

Antibiotics with zero frequencies across all groups were omitted
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Table 3 displays the odds ratios from a univariate, unadjusted logistic regression of
demographic, medical history, and clinical risk factors in cases compared to the negative test
control group and the matched control group. For cases compared to the control group with negative
C. difficile test results, days of hospitalization in the 90 days prior to the test date, prior history of C.
difficile, fever on the test date, and hypotension on the test date were all significantly associated
with C. difficile infection in cases compared to the negative test control group. Increasing days of
hospitalization in the past 90 days prior to the C. difficile test was associated with 1.054 (95% CI
1.017, 1.092) times the odds of having a positive C. difficile infection. Prior history of C. difficile
was associated with 8.333 (95% CI 1.824, 38.063) times the odds of C. difficile infection. For
clinical presentation on the test date, the odds of C. difficile infection were 4.717 (95% CI 1.661,
13.400) for fever and 4.963 (95% CI 1.036, 23.781) for hypotension. In contrast, history of stem
cell therapy was negatively associated with C. difficile infection. Patients with a history of stem cell
therapy were significantly less likely (OR=0.168, 95% CI 0.046, 0.606) to have positive C. difficile
infection.
For the univariate analysis of cases compared to the matched control group, age, prior
history of C. difficile, blood transfusion, having any co-infection, as well as the co-infections of
blood-stream infection, pneumonia, urinary tract infection, and would/skin infection were
significantly associated with risk of C. difficile infection. Increasing age was associated with 1.036
(95% CI 1.013, 1.060) times the odds of having positive C. difficile infection. Patients with a prior
history of C. difficile had 27-fold higher odds of having C. difficile infection (OR=27.035, 95% CI
3.551, 205.826). Patients who received blood transfusion for cancer treatment in the 90 days prior to
index admission were 2.168 (95% CI 1.161, 4.048) times as likely to have C. difficile infection.
Having any co-infection was associated with a 3.830 (95% CI 2.113, 6.944) times the odds of
having C. difficile infection. For specific co-infections, the odds were 3.221 (95% CI 1.102, 9.411)
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for blood stream infections, 5.522 (95% CI 1.672, 18.242) for pneumonia, 3.452 (95% CI 1.281,
9.303) for urinary tract infections, and 6.574 (95% CI 1.725, 25.048) for wound/skin infections.

Table 3: Univariate Logistic Regression of Potential Risk Factors in Cases Compared to
Control Groups

Age
Gender
Male
Female
Days of hospitalization
Prior history of C. difficile
VRE colonization
Cancer type
Hematologic
Solid tumors
Cancer treatment
Blood transfusion
Chemotherapy
History of stem cell therapy
Radiation therapy
Surgery
Indwelling medical devices
Central venous catheter
Enteral feeding
Mechanical ventilation
Nasogastric tube
TPN
Co-infections
Any co-infection
Blood stream infection
Pneumonia
Urinary tract infection
Would/skin infection
Clinical presentation
Elevated creatinine
Elevated lactic acid
Fever
Hypotension
Loose bowel movements
Neutropenia
Tachycardia

Negative Test Control (n=77)

Matched Control (n=152)

OR (95% CI)
1.010 (0.987, 1.034)

OR (95% CI)
1.036 (1.013, 1.060)

1.000
1.000 (0.525, 1.904)
1.054 (1.017, 1.092)
8.333 (1.824, 38.063)
1.752 (0.634, 4.842)

1.000
0.895 (0.488, 1.641)
1.011 (0.993, 1.030)
27.035 (3.551, 205.826)
1.532 (0.624, 3.760)

0.608 (0.316, 1.171)
1.702 (0.863, 3.357)

1.490 (0.625, 3.548)
1.123 (0.494, 2.553)

1.056 (0.552, 2.023)
0.780 (0.390, 1.558)
0.168 (0.046, 0.606)
0.845 (0.271, 2.641)
1.873 (0.927, 3.783)

2.168 (1.161, 4.048)
1.515 (0.760, 3.017)
0.442 (0.115, 1.705)
0.702 (0.247, 1.997)
1.048 (0.503, 2.183)

0.792 (0.406, 1.548)
0.584 (0.135, 2.533)
0.584 (0.135, 2.533)
1.237 (0.500, 3.060)
1.713 (0.395, 7.433)

1.700 (0.913, 3.165)
0.537 (0.104, 2.786)
0.843 (0.204, 3.491)
2.315 (0.962, 5.572)
1.667 (0.509, 5.461)

1.169 (0.621, 2.199)
2.415 (0.711, 8.205)
1.493 (0.537, 4.149)
0.903 (0.372, 2.192)
1.141 (0.416, 3.132)

3.830 (2.113, 6.944)
3.221 (1.102, 9.411)
5.522 (1.672, 18.242)
3.452 (1.281, 9.303)
6.574 (1.725, 25.048)

0.493 (0.044, 5.558)
3.682 (0.972, 13.946)
4.717 (1.661, 13.400)
4.963 (1.036, 23.781)
1.670 (0.858, 3.250)
1.126 (0.573, 2.211)
1.412 (0.680, 2.933)
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A univariate, unadjusted logistic regression was also analyzed for use of various antibiotics
as risk factors in cases compared to both control groups (Table 4). In cases compared to the
negative test control group, receipt of clindamycin and metronidazole in the 90 days prior to test
were significantly associated with risk of C. difficile infection, while receipt of beta-lactams/BLI,
clindamycin, fluoroquinolones, metronidazole, and intravenous vancomycin prior to index
admission were significantly associated with increased risk of C. difficile infection. Clindamycin
was associated with 5.596 (95% CI 1.184, 26.457) times the odds of C. difficile infection if received
at any time in the 90 days prior to test and 18.939 (95% CI 1.074, 333.333) times the odds of C.
difficile infection if received prior to index admission. Metronidazole was associated with 2.303 (95%
CI 1.123, 4.723) times the odds of C. difficile infection if received in 90 days prior to test and 5.978
(95% CI 1.927, 18.541) times the odds of C. difficile infection if received prior to index admission.
The odds of C. difficile infection for antibiotics received prior to admission were 3.852 (95% CI
1.662, 8.926) for beta-lactams/BLI, 2.680 (95% CI 1.351, 5.315) for fluoroquinolones, and 2.475
(95% CI 1.040, 5.889) for intravenous vancomycin.
A greater number of antibiotics were significantly associated with higher risk of C. difficile
infection in cases compared to the matched control group. The odds of C. difficile infection for
antibiotics received in the 90 days prior to index discharge were 4.165 (95% CI 1.271, 13.653) for
beta-lactams, 3.160 (95% CI 1.704, 5.858) for beta-lactams/BLI, 1.870 (95% CI 1.048, 3.336) for
cephalosporins, 6.754 (95% CI 2.924, 15.599) for metronidazole, and 3.048 (95% CI 1.659, 5.600)
for vancomycin. The odds of C. difficile infection for antibiotics received prior to admission were
6.000 (95% CI 1.211, 29.727) for beta-lactams, 8.242 (95% CI 3.126, 21.727) for beta-lactams/BLI,
2.728 (95% CI 1.376, 5.409) for cephalosporins, 5.333 (95% CI 1.415, 20.103) for clindamycin,
5.457 (95% CI 2.669, 11.158) for fluoroquinolones, 33.103 (95% CI 4.412, 248.357) for
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metronidazole, 3.000 (95% CI 1.068, 8.428) sulfonamides, and 8.087 (95% CI 2.722, 24.029) for
intravenous vancomycin.

Table 4: Univariate Logistic Regression of Antibiotic Use in Cases Compared to Control
Groups

Antibiotic received in 90 days prior to test
Beta-lactams
Beta-lactams/BLI
Carbapenems
Cephalosporins
Clindamycin
Daptomycin
Fluoroquinolones
Metronidazole
Sulfonamides
Vancomycin (intravenous)
Antibiotic received prior to admission
Beta-lactams
Beta-lactams/BLI
Cephalosporins
Clindamycin
Daptomycin
Fluoroquinolones
Metronidazole
Sulfonamides
Vancomycin (intravenous)
Antibiotic received at time of test
Beta-lactams
Beta-lactams/BLI
Carbapenems
Cephalosporins
Fluoroquinolones
Metronidazole
Sulfonamides
Vancomycin (intravenous)

Negative Test Control
(n=77)
OR (95% CI)

Matched Control
(n=152)
OR (95% CI)

1.324 (0.467, 3.754)
1.687 (0.892, 3.193)
4.164 (0.455, 38.139)
1.523 (0.804, 2.882)
5.596 (1.184, 26.457)
3.039 (0.122, 75.757)
1.110 (0.590, 2.089)
2.303 (1.123, 4.723)
1.117 (0.444, 2.806)
1.370 (0.725, 2.589)

4.165 (1.271, 13.653)
3.160 (1.704, 5.858)
4.000 (0.733, 21.838)
1.870 (1.048, 3.336)
2.788 (0.983, 7.908)
1.000 (0.091, 11.028)
1.430 (0.811, 2.521)
6.754 (2.924, 15.599)
1.550 (0.671, 3.582)
3.048 (1.659, 5.600)

3.169 (0.619, 16.221)
3.852 (1.662, 8.926)
1.969 (0.908, 4.273)
18.939 (1.0743, 333.333)
3.039 (0.122, 75.757)
2.680 (1.351, 5.315)
5.978 (1.927, 18.541)
1.324 (0.467, 3.754)
2.475 (1.040, 5.889)

6.000 (1.211, 29.727)
8.242 (3.126, 21.727)
2.728 (1.376, 5.409)
5.333 (1.415, 20.103)
1.000 (0.091, 11.028)
5.457 (2.669, 11.158)
33.103 (4.412, 248.357)
3.000 (1.068, 8.428)
8.087 (2.722, 24.029)

1.352 (0.292, 6.251)
0.819 (0.400, 1.676)
3.039 (0.122, 75.757)
0.525 (0.167, 1.645)
0.349 (0.128, 0.955)
0.777 (0.289, 2.088)
1.000 (0.241, 4.151)
1.830 (0.800, 4.190)

In a multivariate logistic regression model comparing cases to the negative test control
group (Table 5), days of hospitalization in the 90 days prior to the test, fever on the test date, prior
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history of C. difficile, and hypotension were all significantly associated with higher likelihoood of C.
difficile infection, adjusting for all other variables. Increasing days of hospitalization was associated
with slightly increased odds of C. difficile infection, at an odds ratio of 1.075 (95% CI 1.027, 1.124).
Fever on the test date was associated with a five-fold increase in likelihood of C. difficile
(OR=5.232, 95% CI 1.460, 18.755) and hypotension on the test date was associated with a nine-fold
increase in likelihood of C. difficile infection (OR=9.245, 95% CI 1.235, 69.183). Prior history of C.
difficile carried the highest likelihood of C. difficile infection of the variables in the model, at a 32fold increase in likelihood of C. difficile infection (OR=32.433, 95% CI 3.513, 299.445). In the
same model, history of stem cell therapy and radiation therapy as cancer treatment in the 90 days
prior to the test were significant for reduced likelihood of C. difficile infection. History of stem cell
therapy was associated with 0.043 times (95% CI 0.006, 0.313) the odds of C. difficile infection,
and patients who received radiation therapy for cancer treatment in the 90 days prior to the C.
difficile test were nine-fold less likely to have C. difficile infection (OR=0.096, 95% CI 0.016,
0.594). All significant variables in the multivariate, adjusted model were also significant in the
univariate model with the exclusion of radiation therapy. Antibiotics that were significantly
associated with increased likelihood of C. difficile in the univariate analysis, however, were not
significant in the multivariate, adjusted model.

Table 5: Multivariate Logistic Regression Compared to Negative Test Control Group
	
  

Characteristic
Days of hospitalization
Fever
History of C. difficile
History of stem cell therapy
Hypotension
Radiation therapy

OR (95% CI)
1.075 (1.027, 1.124)
5.232 (1.460, 18.755)
32.433 (3.513, 299.445)
0.043 (0.006, 0.313)
9.245 (1.235, 69.183)
0.096 (0.016, 0.594)
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For cases compared to the matched control group, the multivariate logistic regression model
showed that age, any co-infection, blood transfusion, cephalosporins, chemotherapy, prior history of
C. difficile infection, metronidazole, and the presence of a nasogastric tube were significantly
associated with higher risk of C. difficile infection. Fluoroquinolones, mechanical ventilation,
radiation therapy, and TPN were associated with lower risk of C. difficile infection, adjusting for all
other variables. Increasing age was associated with slightly increased odds of C. difficile infection
of 1.042 (95% CI 1.006, 1.079). Patients with any co-infection were 5.614 (95% CI 1.878, 16.787)
times more likely to have C. difficile infection. Certain cancer treatments were associated with
increased risk of C. difficile. Blood transfusion was associated with 3.200 (95% CI 1.251, 8.183)
times the odds of C. difficile infection, while chemotherapy was associated with 5.069 (95% CI
1.609, 15.972) times the odds of C. difficile infection. Patients who received cephalosporins in the
90 days prior to the index discharge were 4.214 (95% CI 1.371, 12.952) times more likely to have C.
difficile infection, and patients who received metronidazole were 16.005 (95% CI 3.958, 64.713)
times more likely to have C. difficile infection. Prior history of C. difficile was associated with an
almost 28-fold increase (OR=27.806, 95% CI 2.484, 311.290) in likelihood of C. difficile infection
during the index admission. The presence of a nasogastric tube during the index admission was
associated with a seven-fold increase (OR=6.988, 95% CI 1.339, 36.477) in likelihood of C. difficile
infection. In contrast, receiving fluoroquinolones was associated with a reduced likelihood of C.
difficile infection (OR=0.286, 95% CI 0.097, 0.846), and mechanical ventilation was also associated
with a reduced likelihood (OR=0.056, 95% CI 0.004, 0.817) of C. difficile infection. Patients who
received radiation therapy were 0.117 (95% CI 0.016, 0.872) times as likely to have C. difficile
infection, and patients who received TPN were 0.108 (95% CI 0.015, 0.834) times as likely. The coinfections of blood stream infection, pneumonia, urinary tract infection, and wound/skin infections
were each individually significantly associated with C. difficile infection in the univariate analysis
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but were not significant in the multivariate, adjusted model. In contrast, chemotherapy, mechanical
ventilation, nasogastric tube, radiation therapy, and TPN were not significant in the univariate
model but were significant in the multivariate, adjusted model. Of the antibiotics that were found to
be significant in the univariate model, only receipt of cephalosporins, fluoroquinolones, and
metronidazole in the 90 days prior to the index discharge were significant in the multivariate,
adjusted model.

Table 6: Multivariate Logistic Regression Compared to Matched Control Group
	
  

Characteristic
Age
Any co-infection
Blood transfusion
Cephalosporins
Chemotherapy
Fluoroquinolones
History of C. difficile
Mechanical ventilation
Metronidazole
Nasogastric tube
Radiation therapy
TPN

OR (95% CI)
1.042 (1.006, 1.079)
5.614 (1.878, 16.787)
3.200 (1.251, 8.183)
4.214 (1.371, 12.952)
5.069 (1.609, 15.972)
0.286 (0.097, 0.846)
27.806 (2.484, 311.290)
0.056 (0.004, 0.817)
16.005 (3.958, 64.713)
6.988 (1.339, 36.477)
0.117 (0.016, 0.872)
0.108 (0.014, 0.834)

Discussion
	
  
	
  

The study found several significant associations between C. difficile infection and various

demographic characteristics, clinical factors, antibiotics, and medical history. By using two control
groups, this study was able to find distinct associations for C. difficile-associated diarrhea in
oncology patients presenting with diarrhea (the negative test control group) and for C. difficile
infection in a more general group of oncology patients (the matched control group).
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Cases Compared to the Negative Test Control Group
Between the cases and the negative test control group, univariate, unadjusted analyses found
that the days of hospitalization in the 90 days prior to test, prior history of C. difficile, fever on test
date, hypotension on test date, receipt of clindamycin in 90 days prior to C. difficile test, receipt of
metronidazole in 90 days prior to C. difficile test, receipt of beta-lactams/BLI prior to admission,
receipt of clindamycin prior to admission, receipt of fluoroquinolones prior to admission, receipt of
metronidazole prior to admission, and receipt of intravenous vancomycin prior to admission were
significantly associated with increased likelihood of C. difficile infection. Surprisingly, history of
stem cell therapy was significantly associated with reduction in likelihood C. difficile infection.
However, the associations between the cases and the negative test control group may reflect the
likelihood of positive C. difficile test rather than the odds of disease, as testing bias may impact the
associations.
Days of hospitalization in the 90 days prior to test may be associated with C. difficile
infection for multiple reasons. First, days of hospitalization may reflect severity of underlying
cancers, and subsequently, increased host susceptibility to infection. Recent hospitalization may
also indirectly represent recent exposure to other risk factors, such as antibiotic use and
immunosuppressive therapies, both of which have been implicated as risk factors for C. difficile
infection in previous studies [12, 14]. Days of hospitalization may also correlate to increased
exposure to C. difficile in the healthcare setting through increased length of exposure to any
environmental spores or exposure to asymptomatic carriers of toxigenic strains of C. difficile.
Although most asymptomatic carriage of C. difficile is with non-toxigenic strains, studies have
shown that there are individuals who are asymptomatic and carry toxigenic strains of C. difficile. If
there were patients in the study wards who were asymptomatically colonized with toxigenic strains,
they may have contributed to nosocomial transmission of C. difficile [22, 23]. Prior history of C.
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difficile is another factor in patients’ medical histories that has previously been identified as a risk
factor for C. difficile infection; recurrent C. difficile is common. Relapse rates have been found to
range from 5-23% for metronidazole-treated C. difficile and 9-24% for patients treated with oral
vancomycin [24]. Re-infections are common as well. A study found that 56% of clinical recurrences
of C. difficile are due to re-infections rather than relapses [25]. Thus, patients with prior history of C.
difficile may have been susceptible to re-infection or relapse upon index admission.
In terms of clinical presentation, cases were more likely to present with fever and
hypotension on the day of the C. difficile test compared to patients in the negative test control group,
and these associations were statistically significant. There were higher proportions of cases with
elevated lactic acid in the 90 days prior to test, loose bowel movements in the 90 days prior to test,
neutropenia in the 90 days prior to test, and tachycardia on the test date compared to the negative
test control group, but these differences in proportions were not significant. This finding has
implications for clinicians who are treating cancer patients with diarrhea. Poorer clinical
presentation, particularly fever and hypotension, on days of diarrhea may increase suspicion for C.
difficile infection.
All antibiotics assessed in this study were received in higher proportions in cases compared
to the negative test control group if received in the 90 days prior to the test or prior to admission,
though only a few associations were statistically significant. Receipt of clindamycin and
metronidazole in the 90 days prior to the test were significantly associated with C. difficile infection
in cases compared to the negative test control group, and receipt of beta-lactams/BLI, clindamycin,
fluoroquinolones, metronidazole, and intravenous vancomycin prior to admission (i.e., on a
previous hospitalization within 90 days prior to the index admission) were significantly associated
with C. difficile. The associations between clindamycin, fluoroquinolones, and beta-lactams/BLI
with C. difficile infection are consistent with previous studies [26]. Metronidazole, however, is often
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used as treatment for C. difficile infections, so the association between metronidazole use and C.
difficile may be confounded by recent history of C. difficile, particularly since prior history of C.
difficile was also significantly associated with positive C. difficile test. Intravenous vancomycin has
also previously not been commonly associated with C. difficile infection. However, intravenous
vancomycin is a commonly prescribed antibiotic particularly for empirical use, so the frequency of
intravenous vancomycin received in cases may be more reflective of general antibiotic prescription
practices based on the patients’ poorer clinical presentation or their increased days of hospitalization
prior to C. difficile infection [27].
Of the cancer treatments, history of stem cell therapy was the only significant association,
and the association between history of stem cell therapy and C. difficile infection was negative. This
was an unexpected finding, as stem cell therapy is typically performed in conjunction with
immunosuppressive agents, and immunosuppression is an established risk factor for C. difficile
infection [14, 28]. However, the association found in this study may reflect the higher percentage of
patients in the negative test control group with hematologic cancers compared to the cases.
Additionally, diarrhea is a frequent complication of stem cell transplantation for patients with
lymphoma and multiple myeloma, so there may have been selection bias in the negative test control
group. Patients with lymphoma and multiple myeloma who had a history of stem cell therapy may
have been selected more frequently into the negative test control group because they exhibited
greater frequency of diarrhea than patients with other cancers, which resulted in their stool samples
being tested more frequently [29].
Adjusting for all other variables, the multivariate model comparing cases to the negative
case control group found days of hospitalization, fever on the test date, hypotension on the test date,
and prior history of C. difficile to be significantly associated with C. difficile infection. History of
stem cell therapy was once again associated with reduced likelihood of C. difficile infection, as well
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as radiation therapy in 90 days prior to C. difficile test, which was not significant in the univariate
analysis. Radiation therapy, like stem cell therapy, is typically associated with immunosuppression
and has been associated with decreased intestinal microflora, which is a risk factor for acquisition of
toxigenic C. difficile strains [30]. Thus, this finding was unexpected and a similar association has
not been found in previous studies. Further studies should be conducted to assess for possible
confounders in the negative association between radiation therapy and C. difficile infection. None of
the antibiotics were independently associated with increased risk of C. difficile infection in the
adjusted model that controlled for all other variables; however, this finding does not necessarily
indicate that antibiotic use is not a risk factor for C. difficile infection.

Cases Compared to the Matched Control Group
Between the cases and the control group matched to cases based on hospital ward and date
of discharge, increasing age, prior history of C. difficile, blood transfusion, any co-infection, blood
stream infection, pneumonia, urinary tract infection, and wound/skin infection were significantly
associated with C. difficile infection in the univariate, unadjusted analysis. For the univariate,
unadjusted analysis examining antibiotic use between cases and the matched control group, receipt
of beta-lactams, beta-lactams/ BLI, cephalosporins, metronidazole, and intravenous vancomycin in
the 90 days prior to test were significantly associated with C. difficile infection, and receipt of betalactams, beta-lactams/BLI, cephalosporins, clindamycin, fluoroquinolones, metronidazole,
sulfonamides, and intravenous vancomycin prior to admission were significantly associated with C.
difficile.
The study’s finding of a positive association between increasing age and C. difficile
infection is consistent with previous studies that identified increasing age to be a risk factor for C.
difficile [12]. All co-infections that were assessed in the study were significantly associated with C.
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difficile infection in the univariate analyses, and this is also consistent with previous associations
found between C. difficile and severity of underlying disease [12]. Of cancer treatments, only blood
transfusion was significantly associated with C. difficile infection. Blood transfusion has been
known to cause immunomodulation in the recipient, and in particular, immunosuppression [31]. It is
possible that blood transfusion increased the likelihood of C. difficile infection through
immunosuppression, thereby increasing host susceptibility. Additionally, a study found that in
children with cancer, C. difficile infection was significantly associated with blood transfusions,
possibly due to immunosuppression following blood transfusions [32]. Although our study did not
enroll children under the age of 18, it is possible that in both pediatric and adult oncology patients,
there is a similar mechanism that increases susceptibility to C. difficile infection after receiving
recent blood transfusion; however, the exact mechanism is yet unknown and warrants further
research.
Beta-lactams, beta-lactams/BLI, cephalosporins, clindamycin, and fluoroquinolones have all
been previously associated with C. difficile infection [33]. Although a study has found a significant
association between sulfonamides and C. difficile infection, sulfonamides are a class of antibiotics
that have typically been less frequently associated with C. difficile infection [34]. Intravenous
vancomycin has also previously been rarely associated with C. difficile infection, but in this study,
recent receipt of intravenous vancomycin was significantly associated with C. difficile infection in
univariate analyses in cases compared to both control groups. The identification of antibiotics that
have previously been less commonly associated with C. difficile in this study could reflect changes
in prescription practices or the identification of novel antimicrobial risk factors in C. difficile.
There were several unexpected effects found in the multivariate regression model comparing
the cases to the matched control group. First, receipt of fluoroquinolones in the 90 days prior to the
test appeared to have a negative association with C. difficile infection. However, fluoroquinolones
28

have been previously identified as a risk factor for C. difficile infection in several studies [35, 36].
Consistent with previous studies, the univariate analysis showed an insignificant but positive
association between fluoroquinolones and C. difficile infection for fluoroquinolones received in the
90 days prior to the test, and a significant, positive association between fluoroquinolones received
prior to admission and C. difficile. In our study, antibiotics received in the 90 days prior to the test
was a distinct variable from antibiotics received prior to admission, since the antibiotics received
prior to admission excluded the antibiotics received prior to test but during the index admission. In
the multivariate model, antibiotics used in the 90 days prior to test was included but not the
antibiotics received prior to admission as these variables were overlapping for many of the subjects;
however, the reversal of association found in the multivariate model is still surprising given prior
studies. It is possible that the negative association in the multivariate model is due to
multicollinearity, in which the variable of fluoroquinolones is strongly correlated with another
variable in the multiple regression model, or there could be a confounder in the model. However, it
is not readily apparent whether any of the variables in the model lies in the causal pathway between
fluoroquinolones and C. difficile and would be a confounder of this association. Another possible
explanation is the reversal paradox, also known as the Simpson’s paradox, Lord’s paradox, or the
suppression effect. This paradox refers to the phenomenon in which the association between two
variables is reversed, diminished, or enhanced when additional variables are controlled for [37].
This paradox is commonly observed in conditional analyses in particular, which is consistent with
the use of the conditional multivariate logistic regression for the model comparing cases to the
matched control group [38]. It is possible that the reversal in association for fluoroquinolones and C.
difficile is due to this paradox; however, there is a lack of consensus in the literature regarding the
correct interpretation of results when the reversal paradox occurs, so it is unclear whether the
univariate results or the multivariate results should be considered the true association. However,
29

because there have been numerous studies showing a positive association between fluoroquinolones
and C. difficile infection, it is likely that the positive association found in this study’s univariate
analyses may be more reflective of the true association. The negative association between total
parenteral nutrition and C. difficile also appears to be affected by the reversal paradox in the
multivariate model, as the univariate analysis shows a non-significant but positive association
between TPN and C. difficile. The interpretation of this is less clear, as there have been limited
previous studies examining the association between TPN and C. difficile. This is an association that
warrants further investigation.
Other factors that were not affected by the reversal paradox but negatively associated with C.
difficile infection in the multivariate model comparing cases to the matched control group were
mechanical ventilation on index admission and radiation therapy in the 90 days prior to index
discharge. Radiation therapy was also found to be significantly associated with reduced likelihood
of C. difficile infection in the multivariate analysis comparing cases to the negative test control
group, and poses an unexpected finding. The negative association between C. difficile and
mechanical ventilation was also unexpected, as mechanical ventilation often indicates more severe
underlying disease. Additionally, the association between nosocomial pneumonia and ventilators
has been well established, and ventilators have long been implicated as a major cause of nosocomial
bacterial colonization [39]. Radiation therapy and mechanical ventilation both require further
research to determine the association between these factors and risk of C. difficile infection.
The multivariate model found several significant positive associations for C. difficile
infection. Increasing age, any co-infection, recent blood transfusion, receipt of cephalosporins in the
90 days prior to the index discharge, recent chemotherapy, prior history of C. difficile, receipt of
metronidazole in the 90 days prior to the index discharge, and presence of a nasogastric tube were
associated with increasing likelihood of C. difficile infection. All of these variables were also
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significantly associated with C. difficile infection in the univariate analyses with the exception of
chemotherapy and nasogastric tube. Both chemotherapy and nasogastric tubes have been associated
with C. difficile in previous studies, and this study shows a consistent association [12, 17]. This
study did not examine associations between specific chemotherapeutic agents and C. difficile, but
previous studies have shown particular chemotherapeutic agents to be associated with C. difficile.
Thus, grouping all chemotherapeutic agents as a single variable in this study may have resulted in a
diminished association, and future studies may benefit from examining the associations between
specific chemotherapy drugs and C. difficile infection.

Limitations
There are several limitations to this study. First, the study design was a retrospective, casecontrol chart review. Patient medical records may be incomplete, and missing data can lead to
biased results. In particular, several variables were difficult to find and often incompletely and
inconsistently documented in patient medical records, such as indwelling medical devices and
cancer staging information. Cancer staging data were so sparsely found in patients’ medical records
that the variable was omitted in the analysis, but future studies may find analysis of cancer stage to
be informative in exploring an association between C. difficile and severity of cancer. Patients who
were transferred from outside facilities also often had inconsistently or incompletely documented
charts. There may also be bias due to differential reporting and documentation between cases and
controls. Case patients tended to have poorer prognosis and more complications during their
hospitalizations than control patients, particularly compared to the matched control group. Thus, it
may have been more likely for control patients to have incomplete documentation for various
medical history and clinical factors while cases had more extensive documentation in their charts.
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The selection of control groups also posed a limitation. Subjects for the negative test control
group were selected from a randomized list of patients whose stool samples were submitted to the
Microbiology Lab for C. difficile testing and found to be negative for C. difficile toxin. However, it
is possible that not all patients with diarrhea were tested for C. difficile, as there were no universal
criteria for C. difficile testing in patients with diarrhea in the study hospital. This could have
resulted in selection bias in which more clinically severely ill patients were enrolled as both cases
and as negative test controls, because patients exhibiting milder diarrheal symptoms may not have
had stool samples collected for C. difficile testing, and consequently, not enrolled in the study.
Finally, the matching criteria for the matched control group were kept minimal to two factors –
same hospital ward and date of discharge – in order to identify as many potential risk factors as
possible. Although the matching criteria used in our study were selected to control for
environmental factors, incorporating additional matching criteria may have been able to adjust for
possible confounding variables.
Another limitation with the negative test control group was that C. difficile carriage status
was not documented. Patients who were positive for C. difficile antigen but were negative for C.
difficile toxin in the clinical microbiology laboratory test results were identified to be negative for C.
difficile infection but colonized with non-toxigenic C. difficile. Although patients with C. difficile
colonization are not clinically indicated for treatment and are not considered to have active infection,
studies have shown both common and distinct risk factors for C. difficile colonization compared to
C. difficile infection. Healthcare-associated C. difficile colonization has been associated with
previous hospitalization, chemotherapy, proton-pump inhibitors, H2 blockers, antibodies against
toxin B, stool softeners, and antacids [40, 41]. Thus, by not distinguishing between C. difficile
colonized patients and un-colonized patients in our control groups, this study may have overlooked
the distinct risk factors that may influence C. difficile colonization versus infection.
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The risk period during used in this study was 90 days; however, different studies have used
shorter periods of 60 days or 30 days prior to infection to assess relevant exposures associated with
C. difficile [42, 43, 44]. The use of a longer risk period may have resulted in the identification of
some exposures that may not have been directly associated with C. difficile by the time of diagnosis
for the cases. Finally, this study was conducted in a single institution with a relatively low sample
size. Thus, the results of the study may not be applicable to a larger population of oncology patients,
particularly in different settings where overall C. difficile prevalence may be different than that of
our center.

Conclusions
In conclusion, this study identified several risk factors for C. difficile infection in oncology
patients, both with and without diarrhea and suspicion of C. difficile. These findings may guide
clinicians in selecting appropriate testing for oncology patients who may be at higher risk for C.
difficile infection. Although diarrhea is a common complication in cancer patients, the comparison
between the cases and the negative test control group shows that cancer patients exhibiting diarrhea
with a fever and hypotension may be indicative for C. difficile infection. Additionally, patients with
diarrhea who have lengthy recent hospitalization records and a prior history of C. difficile may be at
increased risk of current C. difficile infection. Based on the analysis of the matched control group,
reduction in cephalosporins and metronidazole use, particularly among patients with any coinfections, presence of a nasogastric tube, a history of C. difficile infection, recent chemotherapy or
blood transfusions may reduce the risk of C. difficile infection and should be a focus of future study
and intervention.
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Appendix: Data Collection Form
	
  

Data Collection Form – C. difficile in Oncology Patients
Subject type: CASE

NEGATIVE TEST CONTROL

HOSPITAL TIME CONTROL

Date of C. difficile test confirmation (cases) or negative test (controls): ____/____/____
Age of subject at test confirmation or at time of hospital admission: _________
Sex:

MALE

FEMALE

Date of index admission: ____/____/____
Date of index discharge: ____/____/____
Days of YNHH hospitalization in 90 days prior to culture: _____________________________
_____________________________
_____________________________
History of C. difficile:

YES

NO

If yes, date of prior diagnosis:___________

Type of Cancer: ________________________________________________________________
Stage:

I

II

III

IV

Not staged

Cancer treatment 90 days prior to test:
Chemotherapy 90 days prior to culture: YES

NO

Date of last chemotherapy treatment: _____/_____/_____
Type:__________________________________________________________________
Surgery:

YES

NO

History of stem cell therapy:

If yes, site(s): ____________________________________
YES

Blood transfusion:

YES

NO

Radiation therapy:

YES

NO

VRE colonization status:

NO

YES

NO

UNKNOWN

Co-infections:

YES

NO

Blood stream infections

Urinary tract infections

Wound/skin infections

Pneumonia

Other: _______________________________
Indwelling medical devices on current admission:
Central Venous Catheter

YES

NO

UNKNOWN

Urinary Catheter

YES

NO

UNKNOWN

Mechanical Ventilation

YES

NO

UNKNOWN

Nasogastric Tube

YES

NO

UNKNOWN

TPN

YES

NO

UNKNOWN

Enteral feeding

YES

NO

UNKNOWN

Antibiotic received 90 days prior to test or discharge:

Antibiotic

Received
(YES/NO)

At time of test
(YES/NO)

Prior to index
admission
(YES/NO)

Discontinued
after
diagnosis?
(YES/NO)

Beta-Lactam
Beta-Lactam + BLI
1st or 2nd generation
cephalosporin
3rd generation cephalosporin
4th generation cephalosporin
Carbapenem
Fluoroquinolone
Tigecycline
Vancomycin (intravenous)
Vancomycin (oral)
Daptomycin
Linezolid
Metronidazole
Clindamycin
Sulfonamide
Rifaxamin
Fosfomycin
Colistin
Other
_______________________
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Clinical presentation:
Temperature on test date: _______________
Tmax 90 days prior to test: _______________
Max heart rate: _______________________
Min blood pressure: ___________________
WBC count: _________________________
Creatinine on admission: _______________
Creatinine on test date: _________________
Neutropenia 90 days prior to test:

YES

NO

Lactic acid 90 days prior to test:

YES

NO

Loose stool 90 days prior to test:

YES

NO

Clinical outcome/treatment:
Treatment: ____________________________________
Transferred to ICU:

YES

NO

Abdominal X-Ray:

YES

NO

CAT Scan:

YES

NO

If yes, evidence of colitis?:

YES

Colectomy:

YES

NO

Death:

YES

NO

UNKNOWN

NO
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